NYR · ASX

Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (ASX:NYR)

AU$0.1

 -0.01 (-8.696%)
ASX:Live
09/05/2025 03:20:17 PM
HALO Price Momentum HALO Ords GROWTH AUS All-Companies
Consensus Score
/10
Recommend
Lock
Target Price
Lock
Deviation
Lock
Unlock Full Consensus Insights

NYR Overview

NYR Health Scores

Short Term

Mean Reversion

Neutral

Trend

Neutral

Event

Neutral

Halo Model

MQV

Very Strong

GARP

Very Strong

MQV Small

Neutral

Valuation

Value

Consensus

Momentum

Price

Very Weak

Earnings

Very Strong

Growth

Earnings

Very Strong

Dividends

Very Strong

Quality

Capital Efficiency

Very Strong

Balance Sheet

Very Strong

About NYR

Website

Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs

Telephone

N/A

Address

Description

N/A

NYR Price Chart

Key Stats

Market Cap

AU$9.84M

PE

N/A

EV/EBITDA

N/A

Dividends Overview

DIV Yield

N/A

Franking

N/A

Ex Dividend Date (est.)

N/A

Market Data

52 weeks range

Low 0.03 - 0.16

Trade Value (12mth)

AU$11,332.00

1 week

4.55%

1 month

9.52%

YTD

25%

1 year

64.29%

All time high

0.46

Key Fundamentals

EPS 3 yr Growth

-71.90%

EBITDA Margin

N/A

Operating Cashflow

-$1m

Free Cash Flow Return

-16.40%

ROIC

-29.80%

Interest Coverage

N/A

Quick Ratio

7.00

Other Data

Shares on Issue (Fully Dilluted)

190m

HALO Sector

Healthcare

Next Company Report Date

N/A

Ex Dividend Date (est.)

N/A

Next Dividend Pay Date (est.)

N/A

Reporting Currency

AUD

Short Sell (% of issue)

0.00

NYR Announcements

Latest Announcements

Date Announcements

08 May 25

NYR-BI03 Extends Cardioprotection to Arrhythmia Control

×

NYR-BI03 Extends Cardioprotection to Arrhythmia Control

02 May 25

Phase I Clinical Trial Dosing Update No 2

×

Phase I Clinical Trial Dosing Update No 2

17 April 25

Results of Meeting

×

Results of Meeting

15 April 25

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

09 April 25

Phase I Clinical Trial Dosing Update No 1

×

Phase I Clinical Trial Dosing Update No 1

09 April 25

Notice of Initial Substantial Holder - M Azzi

×

Notice of Initial Substantial Holder - M Azzi

07 April 25

Significant Neuroprotection in Traumatic Brain Injury Study

×

Significant Neuroprotection in Traumatic Brain Injury Study

31 March 25

First Cohort Dosed in Nyradas Phase I Clinical Trial

×

First Cohort Dosed in Nyradas Phase I Clinical Trial

17 March 25

Nyrada Commences Phase I Clinical Trial Recruitment

×

Nyrada Commences Phase I Clinical Trial Recruitment

12 March 25

2025 EGM Letter to Shareholders, Notice of Meeting and Proxy

×

2025 EGM Letter to Shareholders, Notice of Meeting and Proxy

18 February 25

Appendix 4D and Half Year Report to 31 December 2024

×

Appendix 4D and Half Year Report to 31 December 2024

18 February 25

Nyrada Half Year Results FY2025

×

Nyrada Half Year Results FY2025

07 February 25

Nyrada to Commence Phase Ia Clinical Trial

×

Nyrada to Commence Phase Ia Clinical Trial

23 January 25

Change of Director's Interest Notice - JM

×

Change of Director's Interest Notice - JM

23 January 25

Quarterly Activities Report and Appendix 4C

×

Quarterly Activities Report and Appendix 4C

22 January 25

Change of Director's Interest Notice - CC

×

Change of Director's Interest Notice - CC

22 January 25

Change of Director's Interest Notice - RW

×

Change of Director's Interest Notice - RW

22 January 25

Change of Director's Interest Notice - MF

×

Change of Director's Interest Notice - MF

21 January 25

Notification of cessation of securities - NYR

×

Notification of cessation of securities - NYR

21 January 25

Change of Director's Interest Notice - ID

×

Change of Director's Interest Notice - ID

31 December 24

NYR-BI03 Phase Ia Clinical Trial Update 2

×

NYR-BI03 Phase Ia Clinical Trial Update 2

24 December 24

Nyrada Receives A$1.235M R&D Tax Incentive Rebate

×

Nyrada Receives A$1.235M R&D Tax Incentive Rebate

23 December 24

Upcoming Expiry of Unlisted Warrants

×

Upcoming Expiry of Unlisted Warrants

17 December 24

NYR-BI03 Phase Ia Clinical Trial Update - Correction

×

NYR-BI03 Phase Ia Clinical Trial Update - Correction

16 December 24

NYR-BI03 Phase Ia Clinical Trial Update

×

NYR-BI03 Phase Ia Clinical Trial Update

NYR Fundamentals

Per Share Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Per Share, Growth & Valuations
EPS (Basic) AU$ Lock Lock Lock Lock -0.03 -0.05 -0.01 Lock Lock Lock
EPS (Fully Diluted) AU$ Lock Lock Lock Lock -0.03 -0.05 -0.01 Lock Lock Lock
     Growth % Lock Lock Lock Lock 15.6 -96.5 83.0 Lock Lock Lock
     PE X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     EV/EBITDA X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
CFPS AU$ Lock Lock Lock Lock -0.02 -0.05 -0.01 Lock Lock Lock
FCFPS AU$ Lock Lock Lock Lock -0.02 -0.05 -0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock -24.1 -142.3 87.9 Lock Lock Lock
     Yield % Lock Lock Lock Lock -14.0 -165.5 -7.9 Lock Lock Lock
DPS AU$ Lock Lock Lock Lock 0.00 0.00 0.00 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Yield % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
     Payout Ratio % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
BPS AU$ Lock Lock Lock Lock 0.07 0.03 0.03 Lock Lock Lock
BPS (Tangible) AU$ Lock Lock Lock Lock 0.07 0.03 0.03 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.7 -63.1 1.7 Lock Lock Lock
Shares Outstanding
Diluted m Lock Lock Lock Lock 156 156 163 Lock Lock Lock
Basic m Lock Lock Lock Lock 156 156 163 Lock Lock Lock

Financial Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Income Statement
Sales AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Selling & General Expenses AU$m Lock Lock Lock Lock 5 9 5 Lock Lock Lock
Gross Income AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
     Growth % Lock Lock Lock Lock -163.3 -38.2 21.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cost of Goods Sold to Sales % Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBITDA AU$m Lock Lock Lock Lock -5 -9 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.3 -88.2 50.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Depreciation & Amortisation AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
EBIT AU$m Lock Lock Lock Lock -5 -9 -5 Lock Lock Lock
     Growth % Lock Lock Lock Lock 13.2 -88.2 50.2 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Pretax Income AU$m Lock Lock Lock Lock -5 -9 -5 Lock Lock Lock
Income Taxes AU$m Lock Lock Lock Lock -1 -1 -3 Lock Lock Lock
Net Income AU$m Lock Lock Lock Lock -4 -8 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -12.7 -96.7 82.3 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Cash Flow Statement
Net Operating Cash Flow AU$m Lock Lock Lock Lock -3 -7 -1 Lock Lock Lock
Capital Expenditures AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Investing Cash Flow AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Financing Cash Flow AU$m Lock Lock Lock Lock 0 0 2 Lock Lock Lock
Free Cash Flow AU$m Lock Lock Lock Lock -3 -7 -1 Lock Lock Lock
     Growth % Lock Lock Lock Lock -6.2 -146.1 89.4 Lock Lock Lock
     Margin % Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Franking Balance AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Balance Sheet
Cash & Short-Term Investments AU$m Lock Lock Lock Lock 11 4 5 Lock Lock Lock
Total Assets AU$m Lock Lock Lock Lock 12 5 6 Lock Lock Lock
Long Term Debt AU$m Lock Lock Lock Lock 0 0 0 Lock Lock Lock
Net Debt AU$m Lock Lock Lock Lock -11 -4 -5 Lock Lock Lock
Total Liabilities AU$m Lock Lock Lock Lock 1 1 1 Lock Lock Lock
Equity AU$m Lock Lock Lock Lock 11 4 5 Lock Lock Lock
Invested Capital Lock Lock Lock Lock 11 4 5 Lock Lock Lock
     Growth % Lock Lock Lock Lock -20.7 -63.0 18.6 Lock Lock Lock
Return Ratios
Return on Assets % Lock Lock Lock Lock -33.1 -151.3 -23.5 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.6 -183.5 -27.4 Lock Lock Lock
Return on Total Capital % Lock Lock Lock Lock -37.4 -116.1 -98.0 Lock Lock Lock
Return on Invested Capital % Lock Lock Lock Lock -30.6 -99.2 -29.8 Lock Lock Lock
Cash Flow Return on Invested Capital % Lock Lock Lock Lock -22.6 -91.8 -16.4 Lock Lock Lock

Ratios Records

Historical data

Forecast data

2018 2019 2020 2021 2022 2023 2024 2025 2026 2027
Leverage
Interest Cover X Lock Lock Lock Lock N/A N/A N/A Lock Lock Lock
Debt to EBITDA X Lock Lock Lock Lock 2.2 0.4 1.0 Lock Lock Lock
Net Debt to Equity % Lock Lock Lock Lock -94.1 -87.1 -94.4 Lock Lock Lock
Liquidity
Current Ratio X Lock Lock Lock Lock 25.4 5.8 7.0 Lock Lock Lock
Quick Ratio X Lock Lock Lock Lock 25.4 5.8 7.0 Lock Lock Lock
Cash & ST Inv/Current Assets % Lock Lock Lock Lock 90.4 72.3 81.2 Lock Lock Lock
CFO/Current Liabilities % Lock Lock Lock Lock -621.4 -817.9 -91.4 Lock Lock Lock
Balance Sheet Efficiency
Receivables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Inventory Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Working Capital Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Payables Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Du Pont
Asset Turnover X Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Pretax Margin % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
= Pretax Return on Assets % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
x Tax Rate Complement (1-Tax Rate) % Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Return on Assets % Lock Lock Lock Lock -33.1 -151.3 -23.5 Lock Lock Lock
x Equity Multiplier (Assets/Equity) % Lock Lock Lock Lock 1.0 1.2 1.2 Lock Lock Lock
Return on Equity % Lock Lock Lock Lock -34.6 -183.5 -27.4 Lock Lock Lock
x Earnings Retention (1-Payout) % Lock Lock Lock Lock 100.0 100.0 100.0 Lock Lock Lock
= Reinvestment Rate (%) % Lock Lock Lock Lock -34.6 -183.5 -27.4 Lock Lock Lock
Operating Cycle
Days of Inventory on Hand Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
+ Days of Sales Outstanding Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
Operating Cycle Days Lock Lock Lock Lock 0.0 0.0 0.0 Lock Lock Lock
- Days of Payables Outstanding Days Lock Lock Lock Lock 5,858.7 15,869.6 22,121.2 Lock Lock Lock
Net Operating Cycle Days Lock Lock Lock Lock -5,858.7 -15,869.6 -22,121.2 Lock Lock Lock

Dividends

Key Stats

Ex Dividend Date (est.)

N/A

DIV Yield

N/A

Franking Level

N/A

DPSg

N/A

Quality Yield

Lock

Falling Divs over next 2

Lock

Values and Recommendations

Key Stats

Consensus Score

Lock

Recommendation

Lock

EPS 1 month Change

Lock

Quality Yield

Lock

Falling Divs over next 2

Lock

Halo Consensus Score

Lock Chart

PEG Ratio

Lock Chart

Consensus EPS Revisions

Lock Chart

Short selling

Key Stats

Percent of Issue

0.00%

Value ($M)

0

Prior Change

N/A

7 Day Change

N/A

1 Month Change

N/A

3 Month Change

N/A

Discover
Short-selling
Opportunities

Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.

NYR Shortsell

Frequently Asked Questions

The current share price of Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) is AU$0.1.
The 52-week high share price for Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) is AU$0.16.
The 52-week low share price for Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX)? is AU$0.03.
Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) does not pay a dividend.
Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) does not pay a dividend.
Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) has a franking level of 0.0%.
Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) is classified in the Healthcare.
The current P/E ratio for Nyrada, Inc. Shs Chess Depository Interests Repr 1 Shs (NYR:ASX) is .
logo
Login
Company
Company
Important

Get the latest insights and hot tips delivered right to your inbox

App Store Google Play

HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.